DYSPORT
Drug
Ipsen Innovation
Total Payments
$8.5M
Transactions
16,247
Doctors
5,770
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $87,074 | 4,092 | 2,316 |
| 2023 | $53,386 | 2,675 | 1,609 |
| 2022 | $1.9M | 3,056 | 1,004 |
| 2021 | $1.3M | 1,525 | 668 |
| 2020 | $1.5M | 1,272 | 534 |
| 2019 | $3.7M | 3,385 | 1,154 |
| 2018 | $437.78 | 97 | 36 |
| 2017 | $866.83 | 145 | 60 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 1,485 | 69.5% |
| Consulting Fee | $900,312 | 267 | 10.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $833,527 | 407 | 9.8% |
| Food and Beverage | $340,190 | 13,638 | 4.0% |
| Travel and Lodging | $193,273 | 342 | 2.3% |
| Honoraria | $124,795 | 22 | 1.5% |
| Education | $109,456 | 49 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $56,125 | 30 | 0.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $20,910 | 1 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $19,365 | 6 | 0.2% |
Payments by Type
Research
$5.9M
1,485 transactions
General
$2.6M
14,762 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | Ipsen Innovation | $2.2M | 3 |
| A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | Ipsen Pharma SAS | $1.1M | 0 |
| A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients | Ipsen Innovation | $398,878 | 1 |
| International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh) | Ipsen Pharma SAS | $285,268 | 0 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | Ipsen Innovation | $262,528 | 0 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinumtoxinA in Paediatric Lower Limb Spasticity. | Ipsen Biopharmaceuticals, Inc | $232,480 | 0 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity. | Ipsen Biopharmaceuticals, Inc | $177,093 | 5 |
| Effect of Single Event Multi Level Chemoneurolysis With Dysport on Energy Expenditure and Walking Efficiency | Ipsen Biopharmaceuticals, Inc | $146,557 | 0 |
| APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of DysportabobotulinumtoxinA inPaediatric Lower Limb Spasticity. | Ipsen Biopharmaceuticals, Inc | $130,175 | 0 |
| APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of DysportabobotulinumtoxinA inPaediatric Lower Limb Spasticity | Ipsen Biopharmaceuticals, Inc | $111,262 | 1 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinumtoxinA in Paediatric Lower Limb Spasticity | Ipsen Biopharmaceuticals, Inc | $92,363 | 0 |
| International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort AboLiSh | Ipsen Pharma SAS | $83,092 | 0 |
| Dysport (abobotulinumtoxinA) as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis | Ipsen Biopharmaceuticals, Inc | $69,567 | 0 |
| A PROSPECTIVE, OPEN-LABEL STUDY OF ABOBOTOULINUMTOXIN A DYSPORT FOR THE TREATMENT OF CHRONIC MIGRAINE HEADACHES | Ipsen Biopharmaceuticals, Inc | $68,458 | 0 |
| A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children | Ipsen Innovation | $66,404 | 0 |
| APlacebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerabilityof Abobotulinum Toxin A Dysport as a Treatment for Task-dependent Upper Limb Tremor | Ipsen Biopharmaceuticals, Inc | $58,281 | 0 |
| Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity | Ipsen Biopharmaceuticals, Inc | $39,380 | 0 |
| DYSPORT (ABOBOTULINUMTOXINA) AS AN ADJUNCTIVE TREATMENT TO BRACING IN THE MANAGEMENT OF ADOLESCENT IDIOPATHIC SCOLIOSIS | Ipsen Biopharmaceuticals, Inc | $38,867 | 0 |
| An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice - ULIS III | Ipsen Biopharmaceuticals, Inc | $36,334 | 0 |
| A phase II clinical trial evaluating the safety and effect of abobotulinumtoxin A injection in the gastrocnemius muscle to improve equinus and associated plantar fasciitis pain | Ipsen Biopharmaceuticals, Inc | $36,026 | 0 |
Top Doctors Receiving Payments for DYSPORT — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Physical Medicine & Rehabilitation | Saint Paul, MN | $24,748 | 13 |
| , MD | Pain Medicine | Stanford, CA | $23,942 | 6 |
| , MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $23,923 | 22 |
| , M.D | Sports Medicine | Phoenix, AZ | $23,358 | 36 |
| Asare Christian | Physical Medicine & Rehabilitation | Milwaukee, WI | $22,349 | 31 |
| , MD | Pediatric Rehabilitation Medicine | Orange, CA | $20,223 | 69 |
| , MD | Neurological Surgery | Nashville, TN | $20,048 | 15 |
| , M.D | Neurology | Scottsdale, AZ | $18,313 | 36 |
| , M.D | Neurology | New York, NY | $18,179 | 10 |
| , MD | Orthopaedic Surgery | Chapel Hill, NC | $17,748 | 9 |
| , M.D | Emergency Medical Services | Austin, TX | $16,768 | 38 |
| , MD | Pediatric Rehabilitation Medicine | Washington, DC | $16,476 | 17 |
| , MD | Physical Medicine & Rehabilitation | Houston, TX | $15,717 | 18 |
| , D.O | Dermatology | Philadelphia, PA | $15,200 | 2 |
| , MD | Neurology | New Haven, CT | $14,525 | 8 |
| , M.D | Physical Medicine & Rehabilitation | Columbia, MO | $14,292 | 21 |
| , MD | Pediatric Rehabilitation Medicine | Indianapolis, IN | $14,214 | 26 |
| , M.D | Orthopaedic Surgery | Sacramento, CA | $13,947 | 4 |
| Lin Zhang | Neurology | Sacramento, CA | $11,724 | 16 |
| , MD | Physical Medicine & Rehabilitation | Detroit, MI | $11,385 | 18 |
| Michael Munin | Specialist | Pittsburgh, PA | $10,891 | 5 |
| , MD | Physical Medicine & Rehabilitation | Palo Alto, CA | $10,620 | 2 |
| , M.D | Gynecology | Washington, DC | $10,456 | 3 |
| , MD | Neurology | Warrensville Heights, OH | $10,264 | 11 |
| , DPM | Foot & Ankle Surgery | Saint Louis, MO | $10,184 | 5 |
Ad
Manufacturing Companies
- Ipsen Innovation $3.5M
- Ipsen Biopharmaceuticals, Inc $3.3M
- Ipsen Pharma SAS $1.5M
- Galderma Laboratories, L.P. $140,460
- Ipsen Bioscience Inc $82,588
- Ipsen Biopharm Limited $42,253
Product Information
- Type Drug
- Total Payments $8.5M
- Total Doctors 5,770
- Transactions 16,247
About DYSPORT
DYSPORT is a drug associated with $8.5M in payments to 5,770 healthcare providers, recorded across 16,247 transactions in the CMS Open Payments database. The primary manufacturer is Ipsen Innovation.
Payment data is available from 2017 to 2024. In 2024, $87,074 was paid across 4,092 transactions to 2,316 doctors.
The most common payment nature for DYSPORT is "Unspecified" ($5.9M, 69.5% of total).
DYSPORT is associated with 20 research studies, including "A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus" ($2.2M).